Screening chest wall ultrasound in the mastectomy patient.


Journal

Clinical imaging
ISSN: 1873-4499
Titre abrégé: Clin Imaging
Pays: United States
ID NLM: 8911831

Informations de publication

Date de publication:
Apr 2024
Historique:
received: 09 12 2023
revised: 23 02 2024
accepted: 26 02 2024
medline: 18 3 2024
pubmed: 10 3 2024
entrez: 9 3 2024
Statut: ppublish

Résumé

While there are clear guidelines regarding chest wall ultrasound in the symptomatic patient, there is conflicting evidence regarding the use of ultrasound in the screening of women post-mastectomy. To assess the utility of screening chest wall ultrasound after mastectomy and to assess features of detected malignancies. This IRB approved, retrospective study evaluates screening US examinations of the chest wall after mastectomy. Asymptomatic women presenting for screening chest wall ultrasound from January 2016 through May 2017 were included. Cases of known active malignancy were excluded. All patients had at least one year of clinical or imaging follow-up. 43 exams (8.5 %) were performed with a history of contralateral malignancy, 465 exams (91.3 %) were performed with a history of ipsilateral malignancy, and one exam (0.2 %) was performed in a patient with bilateral prophylactic mastectomy. During the 17-month period, there were 509 screening US in 389 mastectomy patients. 504 (99.0 %) exams were negative/benign. Five exams (1.0 %) were considered suspicious, with recommendation for biopsy, which was performed. Out of 509 exams, 3 (0.6 %) yielded benign results, while 2 (0.39 %) revealed recurrent malignancy, with a 95 % confidence interval (exact binomial) of 0.05 % to 1.41 % for screening ultrasound. Both patients who recurred had previously recurred, and both had initial cancer of lobular histology. Of 509 chest wall screening US exams performed in mastectomy, 2 malignancies were detected, and each patient had history of invasive lobular carcinoma and at least one prior recurrence prior to this study, suggesting benefit of screening ultrasound in these populations.

Sections du résumé

BACKGROUND BACKGROUND
While there are clear guidelines regarding chest wall ultrasound in the symptomatic patient, there is conflicting evidence regarding the use of ultrasound in the screening of women post-mastectomy.
OBJECTIVE OBJECTIVE
To assess the utility of screening chest wall ultrasound after mastectomy and to assess features of detected malignancies.
METHODS METHODS
This IRB approved, retrospective study evaluates screening US examinations of the chest wall after mastectomy. Asymptomatic women presenting for screening chest wall ultrasound from January 2016 through May 2017 were included. Cases of known active malignancy were excluded. All patients had at least one year of clinical or imaging follow-up. 43 exams (8.5 %) were performed with a history of contralateral malignancy, 465 exams (91.3 %) were performed with a history of ipsilateral malignancy, and one exam (0.2 %) was performed in a patient with bilateral prophylactic mastectomy.
RESULTS RESULTS
During the 17-month period, there were 509 screening US in 389 mastectomy patients. 504 (99.0 %) exams were negative/benign. Five exams (1.0 %) were considered suspicious, with recommendation for biopsy, which was performed. Out of 509 exams, 3 (0.6 %) yielded benign results, while 2 (0.39 %) revealed recurrent malignancy, with a 95 % confidence interval (exact binomial) of 0.05 % to 1.41 % for screening ultrasound. Both patients who recurred had previously recurred, and both had initial cancer of lobular histology.
CONCLUSION CONCLUSIONS
Of 509 chest wall screening US exams performed in mastectomy, 2 malignancies were detected, and each patient had history of invasive lobular carcinoma and at least one prior recurrence prior to this study, suggesting benefit of screening ultrasound in these populations.

Identifiants

pubmed: 38460253
pii: S0899-7071(24)00044-5
doi: 10.1016/j.clinimag.2024.110114
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110114

Informations de copyright

Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest Neither I nor my immediate family members have a financial relationship with a commercial organization that may have a direct or direct interest in the content.

Auteurs

Ashley C Bragg (AC)

The University of Texas MD Anderson Cancer Center, United States of America. Electronic address: acbragg@mdanderson.org.

Hannah L Chung (HL)

University of Colorado, United States of America. Electronic address: Hannah.chung@cuanschutz.edu.

Megan E Speer (ME)

The University of Texas MD Anderson Cancer Center, United States of America. Electronic address: mspeer@mdanderson.org.

Kyugmin Shin (K)

The University of Texas MD Anderson Cancer Center, United States of America. Electronic address: kshin1@mdanderson.org.

Jia Sun (J)

The University of Texas MD Anderson Cancer Center, United States of America. Electronic address: JSun9@mdanderson.org.

Jessica W T Leung (JWT)

The University of Texas MD Anderson Cancer Center, United States of America. Electronic address: jwleung@mdanderson.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH